Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Tumor Lysis Syndrome Risk in Outpatient Versus Inpatient Administration of Venetoclax and Hypomethlators for Acute Myeloid Leukemia

Aryeh Pelcovits, MD, Brianna Bakow, MD, Jozal Waroich, Pamela C Egan, MD, Rabin Niroula, MBBS, Adam J Olszewski, MD, John L Reagan, MD

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-133880

Published: 2020

Journal Articles

Cerebrospinal Fluid (CSF) Analysis of Tumor-Specific Cell-Free DNA (cfDNA) As a Diagnostic and Prognostic Tool for Central Nervous System (CNS) Invasion in Lymphoma

Adam J Olszewski, MD, Anna D Chorzalska, PhD, Max Petersen, Thomas A Ollila, MD, Adam Zayac, MD, Habibe Kurt, MD, Diana O Treaba, MD, John L Reagan, MD, Andrew Hsu, MD, Pamela C Egan, MD, James Butera, MD, William Rafelson, MDMBA, Rabin Niroula, MBBS, John Vatkevich, Jordan Robison, CRA, Ilyas Sahin, MD, Chelsea D Mullins, BS, Patrycja M Dubielecka, PhD

Blood (2020) 136 (Supplement 1): 21–22.

https://doi.org/10.1182/blood-2020-134757

Published: 2020

Journal Articles

BrUOG 345: Fractionated Gemtuzumab Ozogamicin Followed By Non-Engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia

Adam Zayac, MD, Pamela C Egan, MD, Thomas A Ollila, MD, Adam J Olszewski, MD, Peter Barth, MD, Matthew I. Quesenberry, MD, James Butera, MD, Loren D. Fast, PhD, Rabin Niroula, MBBS, Peter J. Quesenberry, MD, John L Reagan, MD

Blood (2019) 134 (Supplement_1): 4460.

https://doi.org/10.1182/blood-2019-123789

Published: 2019

Journal Articles

Caplacizumab As Step-up Therapy in Refractory TTP Utilizing Adamts-13 Activity and Evidence of End-Organ Damage

Neel Belani, MD, Adriel Barrios-Anderson, Sc.B, A.B., William Rafelson, MDMBA, Matthew I. Quesenberry, MD, Rabin Niroula, MBBS

Blood (2019) 134 (Supplement_1): 4909.

https://doi.org/10.1182/blood-2019-123206

Published: 2019

Journal Articles

Tumor-Specific Cell-Free DNA (cfDNA) in the Cerebrospinal Fluid (CSF) Detects Cytologically Occult Central Nervous System (CNS) Involvement in Aggressive Lymphomas

Adam J Olszewski, MD, Anna D Chorzalska, PhD, Diana O Treaba, MD, John L Reagan, MD, Pamela C Egan, MD, Habibe Kurt, MD, James Butera, MD, William Rafelson, MDMBA, Alexander C Mohler, MD MS, Thomas A Ollila, MD, Rabin Niroula, MBBS, Jordan Robison, CRA, Chelsea D Mullins, BS, Patrycja M Dubielecka, PhD

Blood (2019) 134 (Supplement_1): 2800.

https://doi.org/10.1182/blood-2019-125475

Published: 2019

NARROW

Tumor Lysis Syndrome Risk in Outpatient Versus Inpatient Administration of Venetoclax and Hypomethlators for Acute Myeloid Leukemia

Cerebrospinal Fluid (CSF) Analysis of Tumor-Specific Cell-Free DNA (cfDNA) As a Diagnostic and Prognostic Tool for Central Nervous System (CNS) Invasion in Lymphoma

BrUOG 345: Fractionated Gemtuzumab Ozogamicin Followed By Non-Engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia

Caplacizumab As Step-up Therapy in Refractory TTP Utilizing Adamts-13 Activity and Evidence of End-Organ Damage

Tumor-Specific Cell-Free DNA (cfDNA) in the Cerebrospinal Fluid (CSF) Detects Cytologically Occult Central Nervous System (CNS) Involvement in Aggressive Lymphomas

Email alerts

ASH Publications

American Society of Hematology

Tumor Lysis Syndrome Risk in Outpatient Versus Inpatient Administration of Venetoclax and Hypomethlators for Acute Myeloid Leukemia

Cerebrospinal Fluid (CSF) Analysis of Tumor-Specific Cell-Free DNA (cfDNA) As a Diagnostic and Prognostic Tool for Central Nervous System (CNS) Invasion in Lymphoma

BrUOG 345: Fractionated Gemtuzumab Ozogamicin Followed By Non-Engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia

Caplacizumab As Step-up Therapy in Refractory TTP Utilizing Adamts-13 Activity and Evidence of End-Organ Damage

Tumor-Specific Cell-Free DNA (cfDNA) in the Cerebrospinal Fluid (CSF) Detects Cytologically Occult Central Nervous System (CNS) Involvement in Aggressive Lymphomas

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only